Pipeline

Hummingbird Bioscience Programs Target Class Discovery Pre-Clinical Phase 1 Clinical Proof of Concept Indication Notes
HMBD-001
Learn More 		HER3 mAb
90% Complete
Squamous NCT05910827
mCRPC NCT05057013
NRG1 fusions/HER3 mutations NCT05919537
HMBD-501
Learn More
 HER3 ADC
30% Complete
Multiple Solid Tumors NCT06956690
HMBD-002
Learn More		 VISTA mAb
90% Complete
Multiple Solid Tumors NCT05082610
HMBD-009
Learn More		 BCMA-TACI (dual-specific) Bispecific under evaluation
50% Complete
Multiple Myeloma
Partnered Programs Target Class Discovery Pre-Clinical Phase 1 Clinical Proof of Concept Indication Notes
HMBD-802
Licensed to Callio Therapeutics		 HER2 ADC
10% Complete
Undisclosed
HMBD-803
Licensed to Callio Therapeutics		 Undisclosed ADC
10% Complete
Undisclosed
HMBD-804
Licensed to Callio Therapeutics		 Undisclosed ADC
10% Complete
Undisclosed
HMBD-011
Licensed to undisclosed party 		VH4-34 mAb
30% Complete
Oncology & Autoimmune
HMBD-002
Learn More
Licensed to Percheron Therapeutics 		VISTA mAb
90% Complete
Multiple Solid Tumors NCT05082610